High serum miR‑484 expression is associated with the diagnosis and prognosis of patients with non‑small cell lung cancer

Zhuang,Zhenli; Sun,Cuiling; Gong,Haitao

doi:10.3892/etm.2019.8010

High serum miR‑484 expression is associated with the diagnosis and prognosis of patients with non‑small cell lung cancer

Authors:
- Zhenli Zhuang
- Cuiling Sun
- Haitao Gong
View Affiliations

Affiliations: Department of Thoracic Surgery, Yantai Yuhuangding Hospital, Yantai, Shandong 264000, P.R. China, Nursing Department, Yantai Municipal Office Hospital, Yantai, Shandong 264000, P.R. China, Department Three of Oncology, Laiyang Central Hospital, Laiyang, Shandong 265200, P.R. China
Published online on: September 17, 2019 https://doi.org/10.3892/etm.2019.8010
Pages: 4095-4102

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the current study was to assess the expression and clinical significance of serum microRNA (miR)‑484 in patients with non‑small cell lung cancer (NSCLC). Reverse transcription‑quantitative polymerase chain reaction was performed to determine the expression of miR‑484 in the serum of patients with NSCLC and NSCLC cell lines. Cell counting kit‑8, flow cytometry, cell migration and cell invasion assays were performed to assess the role of miR‑484 in the malignant changes associated with NSCLC cells. Furthermore, to assess the diagnostic value of miR‑484, receiver operating curve (ROC) analysis was performed and the clinical relevance of serum miR‑484 expression in patients with NSCLC was determined. A Kaplan‑Meier analysis with the log‑rank test was performed to assess the overall survival rate patients. To the best of our knowledge, the current study demonstrates for the first time that serum miR‑484 was increased in patients with NSCLC compared with healthy controls. Additionally, serum miR‑484 was revealed to be positively associated with histological grade, lymph node metastasis, distant metastasis and clinical stage. Patients with NSCLC and high serum miR‑484 levels demonstrated significantly poorer overall survival rates compared with those exhibiting lower serum miR‑484 expressions. ROC analysis revealed that serum miR‑484 could screen patients with NSCLC patients from healthy controls with a high sensitivity and specificity. In vitro analysis also demonstrated that miR‑484 was significantly upregulated in NSCLC cell lines, including 95D and H358 cells. Furthermore, the suppression of miR‑484 decreased cell proliferation, cell migration and invasion. In summary, the results of the present study demonstrated that increased serum miR‑484 expression is associated with the diagnosis and prognosis of patients with NSCLC.

View Figures

View References

1	Tian W, Wang G, Liu Y, Huang Z, Zhang C, Ning K, Yu C, Shen Y, Wang M, Li Y, et al: The miR-599 promotes non-small cell lung cancer cell invasion via SATB2. Biochem Biophys Res Commun. 485:35–40. 2017. View Article : Google Scholar : PubMed/NCBI
2	Wang D, Ma J, Ji X, Xu F and Wei Y: miR-141 regulation of EIF4E expression affects docetaxel chemoresistance of non-small cell lung cancer. Oncol Rep. 37:608–616. 2017. View Article : Google Scholar : PubMed/NCBI
3	Wang H, Shen Q, Zhang X, Yang C, Cui S, Sun Y, Wang L, Fan X and Xu S: The long non-coding RNA XIST controls non-small cell lung cancer proliferation and invasion by modulating miR-186-5p. Cell Physiol Biochem. 41:2221–2229. 2017. View Article : Google Scholar : PubMed/NCBI
4	Wang J, Wang Y, Sun D, Bu J, Ren F, Liu B, Zhang S, Xu Z, Pang S and Xu S: miR-455-5p promotes cell growth and invasion by targeting SOCO3 in non-small cell lung cancer. Oncotarget. 8:114956–114965. 2017.PubMed/NCBI
5	Wang K, Dong L, Fang Q, Xia H and Hou X: Low serum miR-98 as an unfavorable prognostic biomarker in patients with non-small cell lung cancer. Cancer Biomark. 20:283–288. 2017. View Article : Google Scholar : PubMed/NCBI
6	Wang L, Liu W, Zhang YP and Huang XR: The miR-224 promotes non-small cell lung cancer cell proliferation by directly targeting RASSF8. Eur Rev Med Pharmacol Sci. 21:3223–3231. 2017.PubMed/NCBI
7	Wang M, Meng B and Liu Y, Yu J, Chen Q and Liu Y: MiR-124 inhibits growth and enhances radiation-induced apoptosis in non-small cell lung cancer by inhibiting STAT3. Cell Physiol Biochem. 44:2017–2028. 2017. View Article : Google Scholar : PubMed/NCBI
8	Wang P, Chen D, Ma H and Li Y: LncRNA SNHG12 contributes to multidrug resistance through activating the MAPK/Slug pathway by sponging miR-181a in non-small cell lung cancer. Oncotarget. 8:84086–84101. 2017.PubMed/NCBI
9	Wang P, Deng Y and Fu X: MiR-509-5p suppresses the proliferation, migration, and invasion of non-small cell lung cancer by targeting YWHAG. Biochem Biophys Res Commun. 482:935–941. 2017. View Article : Google Scholar : PubMed/NCBI
10	Wang SY, Li Y, Jiang YS and Li RZ: Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 21:4092–4097. 2017.PubMed/NCBI
11	Li J, Tan Q, Yan M, Liu L, Lin H, Zhao F, Bao G, Kong H, Ge C, Zhang F, et al: miRNA-200c inhibits invasion and metastasis of human non-small cell lung cancer by directly targeting ubiquitin specific peptidase 25. Mol Cancer. 13:1662014. View Article : Google Scholar : PubMed/NCBI
12	Meng F, Zhang L, Shao Y, Ma Q and Lv H: MicroRNA-377 inhibits non-small-cell lung cancer through targeting AEG-1. Int J Clin Exp Pathol. 8:13853–13863. 2015.PubMed/NCBI
13	Weber DG, Brik A, Casjens S, Burek K, Lehnert M, Pesch B, Taeger D, Brüning T and Johnen G; MoMar study Group, : Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case-control study. BMC Res Notes. 12:772019. View Article : Google Scholar : PubMed/NCBI
14	do Amaral AE, Cisilotto J, Creczynski-Pasa TB and de Lucca Schiavon L: Circulating miRNAs in nontumoral liver diseases. Pharmacol Res. 128:274–287. 2018. View Article : Google Scholar : PubMed/NCBI
15	Wei J, Gao W, Zhu CJ, Liu YQ, Mei Z, Cheng T and Shu YQ: Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer. 30:407–414. 2011. View Article : Google Scholar : PubMed/NCBI
16	Dinh TK, Fendler W, Chalubinska-Fendler J, Acharya SS, O'Leary C, Deraska PV, D'Andrea AD, Chowdhury D and Kozono D: Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer. Radiat Oncol. 11:612016. View Article : Google Scholar : PubMed/NCBI
17	Ye FG, Song CG, Cao ZG, Xia C, Chen DN, Chen L, Li S, Qiao F, Ling H, Yao L, et al: Cytidine deaminase axis modulated by miR-484 differentially regulates cell proliferation and chemoresistance in breast cancer. Cancer Res. 75:1504–1515. 2015. View Article : Google Scholar : PubMed/NCBI
18	Hu Y, Xie H, Liu Y, Liu W, Liu M and Tang H: miR-484 suppresses proliferation and epithelial-mesenchymal transition by targeting ZEB1 and SMAD2 in cervical cancer cells. Cancer Cell Int. 17:362017. View Article : Google Scholar : PubMed/NCBI
19	Li T, Ding ZL, Zheng YL and Wang W: MiR-484 promotes non-small-cell lung cancer (NSCLC) progression through inhibiting Apaf-1 associated with the suppression of apoptosis. Biomed Pharmacother. 96:153–164. 2017. View Article : Google Scholar : PubMed/NCBI
20	Osmani L, Askin F, Gabrielson E and Li QK: Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol. 52:103–109. 2018. View Article : Google Scholar : PubMed/NCBI
21	Ofori JK, Salunkhe VA, Bagge A, Vishnu N, Nagao M, Mulder H, Wollheim CB, Eliasson L and Esguerra JL: Elevated miR-130a/miR130b/miR-152 expression reduces intracellular ATP levels in the pancreatic beta cell. Sci Rep. 7:449862017. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Wang T, Liu X, Tian Q, Liang T and Chang P: Increasing expression of miR-5100 in non-small-cell lung cancer and correlation with prognosis. Eur Rev Med Pharmacol Sci. 21:3592–3597. 2017.PubMed/NCBI
24	Wang Y, Cong W, Wu G, Ju X, Li Z, Duan X, Wang X and Gao H: MiR-376a suppresses the proliferation and invasion of non-small-cell lung cancer by targeting c-Myc. Cell Biol Int. 42:25–33. 2018. View Article : Google Scholar : PubMed/NCBI
25	Wang Z, Liu Z, Fang X and Yang H: MiR-142-5p suppresses tumorigenesis by targeting PIK3CA in non-small cell lung cancer. Cell Physiol Biochem. 43:2505–2515. 2017. View Article : Google Scholar : PubMed/NCBI
26	Wei K, Pan C, Yao G, Liu B, Ma T, Xia Y, Jiang W, Chen L and Chen Y: MiR-106b-5p promotes proliferation and inhibits apoptosis by regulating BTG3 in non-small cell lung cancer. Cell Physiol Biochem. 44:1545–1558. 2017. View Article : Google Scholar : PubMed/NCBI
27	Yi R, Feng J, Yang S, Huang X, Liao Y, Hu Z and Luo M: miR-484/MAP2/c-Myc-positive regulatory loop in glioma promotes tumor-initiating properties through ERK1/2 signaling. J Mol Histol. 49:209–218. 2018. View Article : Google Scholar : PubMed/NCBI
28	Merhautova J, Hezova R, Poprach A, Kovarikova A, Radova L, Svoboda M, Vyzula R, Demlova R and Slaby O: miR-155 and miR-484 Are associated with time to progression in metastatic renal cell carcinoma treated with sunitinib. Biomed Res Int. 2015:9419802015. View Article : Google Scholar : PubMed/NCBI
29	Halvorsen AR, Sandhu V, Sprauten M, Flote VG, Kure EH, Brustugun OT and Helland Å: Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab. Acta Oncol. 57:1225–1231. 2018. View Article : Google Scholar : PubMed/NCBI
30	Chen X, Hu Z, Wang W, Ba Y, Ma L, Zhang C, Wang C, Ren Z, Zhao Y, Wu S, et al: Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer. 130:1620–1628. 2012. View Article : Google Scholar : PubMed/NCBI